Geriatric hypertension: the growing use of calcium-channel blockers

J C Busse1, B J Materson

  • 1University of Miami.

Geriatrics
|February 1, 1988
PubMed

Insights

Essential hypertension requires individualized treatment. Calcium-channel blockers offer a targeted approach for elderly patients, managing hypertension effectively while minimizing side effects and improving comorbidities.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Essential hypertension is a complex condition requiring tailored treatment strategies.
  • Elderly hypertensive patients present unique challenges due to increased medication sensitivity and comorbidities.
  • Current antihypertensive therapies may have significant side effects in older populations.

Purpose of the Study:

  • To evaluate the role of calcium-channel blockers in managing hypertension in elderly individuals.
  • To highlight the advantages of calcium-channel blockers over other antihypertensive agents for this demographic.

Main Methods:

  • This study reviews the pathophysiologic mechanisms of hypertension relevant to elderly patients.
  • It analyzes the pharmacological properties and clinical outcomes associated with calcium-channel blockers.
  • Comparative efficacy and safety data against other antihypertensive classes are discussed.

Main Results:

  • Calcium-channel blockers target key pathophysiologic pathways in hypertension.
  • These agents demonstrate a favorable side-effect profile compared to other antihypertensives in the elderly.
  • Calcium-channel blockers can positively impact certain coexisting medical conditions in elderly hypertensives.

Conclusions:

  • Calcium-channel blockers represent a valuable therapeutic option for individualized hypertension management in the elderly.
  • Their specific mechanisms and tolerability make them suitable for addressing the complexities of geriatric hypertension.
  • These agents offer a promising approach to improve treatment outcomes and quality of life in older hypertensive patients.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...